Wall Street Associates’s Standard BioTools LAB Stock Holding History

Wall Street Associates’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-70,069	Closed	-$2.95M	–	342
2015 Q1	$2.95M	Buy	70,069 +14,089	+25%	+$557K	0.28%	111
2014 Q4	$1.89M	Sell	55,980 -3,495	-6%	-$99K	0.18%	153
2014 Q3	$1.46M	Sell	59,475 -9,590	-14%	-$270K	0.15%	171
2014 Q2	$2.03M	Sell	69,065 -7,500	-10%	-$240K	0.17%	165
2014 Q1	$3.37M	Sell	76,565 -1,100	-1%	-$48.4K	0.28%	122
2013 Q4	$2.97M	Sell	77,665 -4,330	-5%	-$128K	0.24%	130
2013 Q3	$1.8M	Sell	81,995 -2,346	-3%	-$46.1K	0.17%	167
2013 Q2	$1.47M	Buy	+84,341	New	+$1.48M	0.15%	169

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wall Street Associates's LAB Position: Q2 2015 in Review

Wall Street Associates sold out of Standard BioTools (LAB) in Q2 2015, closing a stake of 70,069 shares — an estimated $2.95M sold.

Wall Street Associates first reported a position in LAB in Q2 2013 and held it in 8 quarters. The position peaked at $3.37M in Q1 2014. 107 funds tracked by Wall St. Rank hold LAB as of Q2 2015.

Wall Street Associates reported no remaining Standard BioTools position as of Q2 2015 after selling out during the quarter.
Wall Street Associates sold 70,069 Standard BioTools shares in Q2 2015, an estimated $2.95M.
Wall Street Associates first reported a position in Standard BioTools in Q2 2013 and held it in 8 quarters.
Wall Street Associates's Standard BioTools position peaked at $3.37M in Q1 2014.
107 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2015.

Based on Wall Street Associates's 13F filing for Q2 2015, filed 13 Aug 2015.